Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 1—January 2004

Dispatch

Human Infection with M- Strain of Brucella canis

Jorge C. Wallach*†Comments to Author , Guillermo H. Giambartolomei†, Pablo C. Baldi†, and Carlos A. Fossati†‡
Author affiliations: *Hospital F. J. Muñiz, Buenos Aires, Argentina; †IDEHU, Universidad de Buenos Aires, Buenos Aires, Argentina; ‡Universidad Nacional de La Plata, La Plata, Argentina

Main Article

Table

Cellular immune response in vitro to Brucella cytoplasmic proteinsa

Antigen Lymphocyte proliferation (SI) IL-2b (fold increase) IFN-γb (fold increase) IL-10b (fold increase)
Before therapy BLS 4 8 3 3
CP 3 10 7 4.5
End of therapy BLS 1 1 2 1
CP 2.5 6 4 2
55 days after end
of therapy BLS 1 1 1 1
CP 1 1 3 1

aBLS, Brucella lumazine synthase; CP, cytoplasmic proteins; SI, stimulation indices; IL, interleukin; IFN, interferon.
bBy reverse transcription-polymerase chain reaction.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO